Laurus labs AGM 2023 notes
Companies like Laurus who conducts regular earning call quarterly, AGM meeting usually doesn’t add more info. Capturing points from AGM 2023 I thought will be interesting for investors
FY24 expect to be flat year in terms of Revenue, due to Paxlovid revenue loss as guided by end of FY23.
FY25 Revenue growth to be driven by commercialization of Phase 3 molecules, including one in agro chem division, in addition to multi product contract on animal health products.
ImmunoACT investment expected to start yielding returns from FY25 as well pending approval and commercialization.
Expect to have 70% utilization for Unit2 (Formulations) by end of the year. No plans to increase Unit 2 capacity so far.
I was under the impression ImmunoACT investment is for long term (5 year+) and didn’t expect any revenue generation anytime soon. But looks like it can happen in FY25. Anyone has anymore info feasibility of this ?
If true, Laurus exhibits remarkable foresight in recognizing future potential different entrepreneurs and effectively leveraging it to enhance their capabilities, as evidenced by the achievements of both Laurus Bio and immunoACT.
| Subscribe To Our Free Newsletter |
